A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

NCT05307679 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
7
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated due to sponsor decision and not related to safety or tolerability.

Conditions

Interventions

Sponsor

Hoffmann-La Roche